IP Library Granted Patent US 6,858,590
Granted Patent B2
US 6,858,590 · App. 09/929,955 · Granted Feb 22, 2005

Vaccines containing ribavirin and methods of use thereof

Assignee: TRIPEP AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,858,590
App. No.
09/929,955
Granted
Feb 22, 2005
Kind
B2
Abstract

Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.

Claims (29)

1. An immunogenic composition comprising nucleic acid molecule encoding a viral antigen polypeptide and ribavirin for co-administration thereof.

2. The immunogenic composition of claim 1 , wherein said nucleic acid molecule encodes a hepatitis antigen.

3. The immunogenic composition of claim 2 , wherein said hepatitis antigen is a hepatitis C viral antigen.

4. The immunogenic composition of claim 3 , wherein said hepatitis C viral antigen comprises NS3.

5. The immunogenic composition of claim 2 , wherein said hepatitis C viral antigen comprises NS4A.

6. The immunogenic composition of claim 1 , wherein said nucleic acid molecule comprises the sequence of SEQ. ID NO. 16.

7. The immunogenic composition of claim 1 , wherein said nucleic acid molecule comprises a fragment of the sequence of SEQ. ID NO. 13 that encodes an antigenic peptide.

8. A method of making an immunogenic composition comprising:

providing ribavirin;

providing a nucleic acid that encodes a viral antigen; and

combining said ribavirin and said nucleic acid to formulate said immunogenic composition.

9. A method of making an immunogenic composition comprising:

providing ribavirin;

providing a nucleic acid that encodes a hepatitis antigen; and

combining said ribavirin and said nucleic acid to formulate said immunogenic composition.

10. A method of making an immunogenic composition comprising:

providing ribavirin;

providing a nucleic acid that encodes a hepatitis C antigen; and

combining said ribavirin and said nucleic acid to formulate said immunogenic composition.

11. A method of making an immunogenic composition comprising:

providing ribavirin;

providing a nucleic acid, that encodes a hepatitis C antigen comprising NS3; and

combining said ribavirin and said nucleic acid to formulate said immunogenic composition.

12. A method of making an immunogenic composition comprising:

providing ribavirin;

providing a nucleic acid that encodes a hepatitis C antigen comprising NS4A; and

combining said ribavirin and said nucleic acid to formulate said immunogenic composition.

13. The immunogenic composition of claim 1 , wherein said viral antigen encodes a polypeptide comprising the sequence of SEQ ID NO:17.

14. The immunogenic composition of claim 1 , wherein said viral antigen encodes a peptide comprising an antigenic fragment of the sequence of SEQ. ID NO. 1.

Assignments (6)
SECURITY INTEREST Recorded Sep 29, 2015
From: TRIPEP AB
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 036714/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2014
From: CHRONTECH PHARMA AB
To: TRIPEP AB
Reel/Frame 034521/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: CHRONTECH PHARMA AB
To: AVAC PHARMA LIMITED
Reel/Frame 034442/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: AVAC PHARMA LIMITED
To: CHRONTECH PHARMA AB
Reel/Frame 034442/0817 →
CHANGE OF NAME Recorded Apr 14, 2010
From: TRIPEP AB
To: CHRONTECH PHARMA AB
Reel/Frame 024233/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2003
From: SALLBERG, MATTI; HULTGREN, CATHARINA
To: TRIPEP AB
Reel/Frame 014073/0007 →
Continuity (3)
Provisional Application 6022576700 · Aug 17, 2000
Provisional Application 6022917500 · Aug 29, 2000
Related Publication 20020136740A1 · Sep 26, 2002